Powered by WPeMatico
Powered by WPeMatico
Powered by WPeMatico
Powered by WPeMatico
Mumbai: Over the past five years, more than 43,000 women have donated breast milk to Sion Hospital, which is home to Asia’s first breast milk bank, according to the Brihanmumbai Municipal Corporation (BMC). The donations from 43,412 lactating mothers have benefited 10,523 newborns, according to the data released by the civic body during the National Breastfeeding Month in August.
Breast milk donations play a crucial role in bringing down mortality rates among low-weight premature and at-risk newborns. Talking to PTI, Dr Mohan Joshi, dean of Sion Hospital, said, “The milk bank was started in 1989 by Armida Fernandes, and it received donations of Rs 1 lakh from Tata Group’s Indian Hotels Company Limited when Ajit Kerkar was its chairman. It’s the first breastmilk bank in Asia.”
He said mother’s milk is special because it contains haemoglobin and vital vitamins essential for a newborn’s growth and development.
Acording to the PTI report, the donations at the breastmilk bank have supported infants with low birth weight and insufficient growth and babies of women who are unable to breastfeed due to postnatal complications.
The hospital is now helping medical establishments in western India to set up similar milk banks.
Dr Swati Manerkar, head of the neonatology department, said, “The objective of the milk bank is to ensure that no infant dies due to scarcity of breastmilk. We take all safety precautions while procuring milk from donors. We approach lactating mothers who can give their milk once they have fed their babies”, news agency PTI reported.
The milk is then processed in the pasteurisation area, and once cleared, it is stored at -40 degrees Celsius, she said.
Dr Manerkar said milk is given when prescribed by doctors.
“The milk bank helps around 2,000 to 2,500 newborns each year, she said, adds PTI.
Also Read:Mumbai’s Sion Hospital reopens Skin Bank with advanced technology
Powered by WPeMatico
Mumbai: Global pharma major Lupin Limited has announced that it has signed a distribution agreement with Scope Ophthalmics Ireland (SCOPE) for the registration and marketing of a Moist Heat Mask, a Tea Tree Oil Eyelid Cleansing Gel and Tea Tree Oil Eyelid Wipes of the OPTASE range, in Mexico.
The OPTASE range is a safe, tested and expert recommended 3-step regime to help tackle the cause and symptoms of eye conditions such as Dry Eyes, Blepharitis and Meibomian Gland Dysfunction (MGD). This eye care routine comprising of Heat, Cleanse, and Hydrate, follows the TFOS Dry Eye management strategy, as outlined in the DEWS II publication’s staged plan.
“We are very pleased to collaborate with SCOPE and integrate a part of their OPTASE range of products into our Ophthalmology offerings. This expansion of our Ophthalmology range reinforces our commitment to enhancing vision care for our patients, improving their quality of life,” said Dr. Fabrice Egros, President – Corporate Development and Growth Markets, Lupin.
“Through the signature of this collaboration with Lupin, SCOPE is expanding its footprint in Latin America for its OPTASE range. Mexico is clearly a country of strategic importance for SCOPE where our innovative eyecare products, together with the strong relationships of Lupin amongst Eye Care Professionals as well as its overall credibility in the market, will certainly contribute to the success of both companies” said Tom Freyne, CEO at SCOPE.
Powered by WPeMatico
Gujarat- The Director of Medical Education (DME) Gujarat is going to end the UG online choice filling for the 2nd round of BAMS and BHMS courses for the academic year 2024.
The 2nd round of online choice filling will end on 03rd October 2024 at 12:00 Noon. The choices filled by the candidates will be displayed on 03rd October 2024 at 02:00 pm. To participate in the 2nd Round, the candidates have to log in to the official website of DME Gujarat using their User ID and Password to give online consent for participation in the 2nd Round.
SCHEDULE
|
S.NO |
DETAILS |
DATE AND TIME |
|
|
FROM |
TO |
||
|
1 |
2nd Round Choice Filling |
28/09/2024 |
03/10/2024 12:00 Noon |
|
2 |
Display of Choices filled by candidates |
03/10/2024 up to 02:00 pm |
|
PROCESS OF PARTICIPATION FOR 2ND ROUND
1 All the candidates, included in the Merit List of ACPUGMEC, can participate in the 2nd Round, irrespective of the admission status of the candidate of the 1st Round.
2 If any candidate has not taken part in the 1st Round in ACPUGMEC, can also register in Round 02 and participate in the 2nd Round Choice filing.
3 If the candidate, who has confirmed admission to the 1st Round and has given consent to participate in the second round, has been allotted a new seat, the admission to the first round will get automatically cancelled.
4 If the candidate takes part in the 2nd Round of ACPUGMEC and his/her admission does not get upgraded then his/her admission of the 1st Round will be continued.
5 The candidate, who has participated or not participated in 2nd Round, the admission to the 1stRound can also be upgraded in the same college by change of admission category (i.e., ST / SC / SEBC / EWS to General category or PwD to non-PwD seat), there is no need to report the help centre for confirmation of admission.
GUIDELINES OF CHOICE FILLING
1 Online allotment of seats is done on the basis of merit cum choice in institutes permitted by the concerned council.
2 Candidates are instructed to fill all the available choices irrespective of the institute’s status (permitted /recognized) so that during the process of allotment if any institute gets permission, you can get admission in that seat.
3 The choices can be decided by the candidate on the following criteria-
i Course of choice.
ii Institute/Place of choice.
iii Government or Self-financed Institute.
iv Tuition fees.
STEPS FOR CHOICE FILLING
STEP 1- Click on the “Ayurvedic & Homeopathy” tab under “Undergraduate Admission”.
STEP 2- Click on the “Login for Undergraduate Ayurvedic & Homoeopathy Admission” button.
STEP 3- Click on “Candidate Registration/Login”.
STEP 4- Enter your USER ID (Sr No. of PIN), Password, 14-digit PIN, and Captcha & Click on the Submit button.
STEP 5- Click on “CHOICE DETAILS”.
STEP 6- Click on “Available Choice” to start the process of choice filling.
STEP 7- Click on “Consent and Fill Choice” to start the process of choice filling.
To view the schedule, click the link below
Powered by WPeMatico
Once a sufficient number of doctors and paramedical staff are available, the arrangements in the district hospitals as well as community and primary health centres will improve, Shukla said on Sunday.
Powered by WPeMatico
New Delhi- Through a notice, the Indian Council of Medical Research (ICMR) has called for concept proposals for the Centre for Advanced Research (CAR), under the Extramural Research Program.
The Last Date for concept proposal is November 21, 2024. Under its Extramural Research Programme, the Indian Council of Medical Research (ICMR) funds the Centre for Advanced Research (CAR) to promote advanced research by experienced research teams.
What the CAR is expected to do:
Conducting decisive research that helps in solving an important healthcare problem by a research team. It can have single or multiple linked research projects with clear deliverables. It encourages in-depth research, to generate new knowledge and solutions for health problems in multiple aspects of causation, progression, management and prevention.
Priority diseases or conditions:
Research teams planning to undertake studies in finding solutions for prevention, screening, diagnosis, treatment or rehabilitation of the following diseases or conditions will receive preference for selection as CAR.
Tentative Timeline:
Last date of submission: 21-Nov-2024; 1700hrs (Thursday)
Review and short listing: 03-Jan-2025
Detailed proposal submission: 31-Jan-2025
Final selection: 15-Feb-2025
Release of fund: 21-Mar-2025
Important note for the submission of proposal:
1. Submission portal is open
2. After completing mandatory section of PI profile, Go to Proposal submission → Click on Call for proposal → Click on ‘Apply Proposal’ → Select ‘Call for Centre for Advanced Research (CAR),under Extramural Research Program, ICMR – 2024’ from the dropdown → Click on ‘Apply New Proposal’ and fill the form step by step.
3. Kindly ensure that all sections are adequately filled with the necessary details.
4. Inclusion of at least one Co-PI from PI’s institute is mandatory.
5. PIs are advised to submit proposal well ahead of the last date, since servers may be overloaded and slow to respond.
6. For technical concerns related to the application process, please mail to po.epms@icmr.gov.in
Duration of project and funding:
Current budgetary ceiling is between INR 8 crores to less than INR 15 crores per CAR. Duration of project will be for a maximum period of five years.
How to apply
A proposal can be submitted for financial support through ONLINE MODE ONLY by the Principal Investigator on behalf of the proposed team of Scientists/ professionals who have a regular employment in Medical Institutes/ Research Institutes/ Universities/ Colleges/ recognized Research & Development laboratories/ Government and semi-government organizations and Non-Governmental Organizations. The research team should have credentials for relevant skills, experience and demonstrated ability to solve health problems under consideration.
Research teams with outstanding achievements, recognition and proven excellence in the area and having the necessary infrastructure to carry out further work are encouraged to apply.
The institute and principal investigator will be supported to establish CAR with an aim that the facility so created would continue to function even after this funding gets over. CAR should develop trained health research personnel. After completion of the project, the host institute would be expected to take over activities of the centre as permanent activity.
ICMR scientists/institutes are not eligible to apply under this call. ICMR scientists may be named as coinvestigators in these projects, but no funds will be given for ICMR institutions or scientists in these cases. Format for project proposal is provided at Annexure-I & II.
Table-1: Priority Diseases and conditions
|
Communicable Diseases |
Non-Communicable Diseases |
Reproductive, Maternal and Child Health, Nutrition |
|
One Health |
Cancer |
Anaemia & micronutrient deficiencies |
|
AMR |
Cardiovascular diseases |
Childhood malnutrition |
|
Tuberculosis |
Diabetes Mellitus |
Early childhood development (particularly improving neuro-developmental outcomes of small and sick newborns) |
|
Vector Borne diseases |
Chronic Kidney Disease |
Neonatal Mortality, preterm-LBW, asphyxia, neonatal sepsis |
|
Respiratory infections |
Chronic Respiratory diseases |
Genetic disorders/congenital anomalies |
|
Neurological infections |
Neurological conditions |
PCOS/ endometriosis |
|
Hepatic infections |
Mental Health |
Antenatal, intra-natal and postnatal care |
|
Sepsis |
Blood disorders including hemoglobinopathies |
Post-conception care |
|
HIV/AIDS & other STIs |
Rare diseases |
Obstetric haemorrhage |
Over-arching:
Ageing and disabilities
Oral Health
Mitigating Health impacts of Climate Change
Format for submission of Concept note for Centre for Advanced Research
1. Title of the proposed CAR (up to 30 words): should be specific, concise and yet sufficiently descriptive and informative.
2. Summary (up to 1500 words): A structured summary should contain the following subheadings:
a. Rationale/ gaps in existing knowledge (300 words),
b. Novelty (200 words)
c. Objectives (100 words)
d. Methods (500 words)
e. Expected outcome (200 words)
f. Evidence for expertise on specific area of research (200 words)
Experts will review and score each project proposal. The scoring criteria are as follows:
1. Skill and experience of Research team (PI, CoPI): 05
2. Publications* (01-April-2017 to 31-Mar-2024) including IF? 05
3. Impact of publications on (public health or clinical protocol) 10
4. Concept note:
o Choice of the problem for research on solutions 02
o Novelty and appropriateness of methods 02
o Likelihood of success 02
o Possible impact expected 04
Total 30
(* Publications as first, last or corresponding authors)
To view the official Notice, Click here : https://medicaldialogues.in/pdf_upload/car20242-253482.pdf
Powered by WPeMatico
New Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the drug major GlaxoSmithKline’s protocol amendment proposal for the clinical trial titled “A Phase 2, Randomized, Parallel, Open-Label Study to Investigate the Safety, Efficacy, and Pharmacokinetics of Various Dosing Regimens of Single-Agent Belantamab Mafodotin (GSK2857916) in Participants with Relapsed or Refractory Multiple Myeloma (DREAMM-14).”
This came after GlaxoSmithKline Pharmaceuticals presented protocol amendment 03 dated 25 June 2024 protocol no. 209628.
Belantamab mafodotin is a monoclonal antibody conjugated with a cytotoxic agent for the treatment of relapsed and refractory multiple myeloma. Belantamab mafodotin is a humanized IgG1κ monoclonal antibody against the B-cell maturation antigen (BCMA) conjugated with a cytotoxic agent, maleimidocaproyl monomethyl auristatin F (mcMMAF). The antibody-drug conjugate binds to BCMA on myeloma cell surfaces causing cell cycle arrest and inducing antibody-dependent cellular cytotoxicity.
Belantamab mafodotin is indicated for the treatment of adults with relapsed or refractory multiple myeloma who have received at least four prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.
At the recent SEC meeting held on 18 September 2024, the expert panel reviewed protocol amendment 03, dated 25 June 2024, protocol no. 209628.
After detailed deliberation, the committee recommended the approval of the protocol amendment presented by the firm.
Also Read:Drugs in CDSCO samples Counterfeit, not ours, say leading pharma companies
Powered by WPeMatico